INVO Fertility Secures Patent for Modified INVOcell Device Through 2040

Event summary

  • INVO Fertility received a U.S. patent (No. 12,544,204 B2) for a modified INVOcell® device on February 10, 2026.
  • The patent extends intellectual property protection for the device through 2040.
  • The modified design simplifies the original INVOcell device by removing the microchamber.
  • INVOcell is the first FDA-cleared intravaginal culture (IVC) system for assisted reproductive care.
  • The company operates two INVO Centers and one IVF clinic in the U.S.

The big picture

INVO Fertility's patent issuance strengthens its intellectual property foundation, supporting its growth strategy in the fertility market. The modified INVOcell device offers a patient-centered alternative to traditional IVF, aligning with broader industry trends toward more natural and affordable assisted reproductive technologies. The company's focus on expanding its clinic network and device distribution positions it to capture a larger share of the growing fertility services market.

What we're watching

IP Strategy
How the extended patent protection will influence INVO Fertility's competitive positioning in the fertility market.
Clinical Adoption
The pace at which the modified INVOcell device will be adopted by third-party fertility clinics.
Regulatory Compliance
Whether the FDA's previous clearances for the INVOcell device will facilitate smoother approvals for future modifications.